Note: Ingredients listed on restricted chemical lists
EC/CAS
203-632-7/108-95-2
Name of the chemical
Phenol
Concentration
<0.5%
General Information
Version
1.0.0
Revision date
2016-05-09
Product name
Neostigmine Methylsulfate Injection
Product name
Neostigmine Methylsulfate Injection
Identification on the label/Trade name
Not applicable
Product Synonyms
(m-hydroxyphenyl) trimethylammonium methylsulfate dimethylcarbamate
Chemical name
Mixture
1.2.1 Relevant identified uses
Bulk formulated pharmaceutical mixture/Formulated pharmaceutical product/ of the substance or mixture packaged in final form for patient use mixture and uses
Emergency telephone
+1 (800) 424-9300, +1 (703) 527-3887
Icons in SDS
Company Information
company name
Par Sterile Products
e-mail address of the competent person responsible for the Safety Data Sheet
drugsafety@parpharm.com
GHS Information
Signal word
Warning
Hazard Codes
Hazard statements (CLP)
H302
Hazard statements
Code
Statements
H302
Harmful if swallowed
Section 2
SECTION 2: Hazards identification
(EC) No 1272/2008 Classification of the substance or mixture Drugs in the finished state and intended for the final user are not subject to labeling in the US, EU or Canada. Please consult the prescribing/packaging information. The classification and labeling listed below is for bulk drug product HAZARDS IDENTIFICATION …continued Globally Harmonized Acute toxicity - oral - Category 4. System [GHS]
Signal word
Warning
Hazard statements
H302 - Harmful if swallowed. when using this product. P301+P312 IF SWALLOWED Call a Poison Center or doctor/physician if you feel unwell. P330 - Rinse mouth. P501 - Dispose of contents/container to location in accordance with local/regional/national/ international regulations.
Precautionary statements
P264 - Wash hands thoroughly after handling. P270 - Do not eat, drink or smoke
2.3 Other hazards
Neostigmine methylsulfate is a cholinesterase inhibitor indicated for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery. It may also be used to treat myasthenia gravis. It is usually give subcutaneously or intramuscularly, at a dose of 0.25 to 0.5 mg. Side effects may include salivation and excess bronchial secretions and runny nose, muscle tremors, bowel cramps and diarrhea, heartbeat irregularities, and increased urination. Overdosage may lead to increasing muscle weakness and respiratory arrest due to cholinergic crisis. Note
2.1 Classification of the substance or mixture
Drugs in the finished state and intended for the final user are not subject to substance or mixture
